A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Trial details
- Registry ID
- NCT07210723
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated CardiomyopathyNCT07210723 | KARD | Phase 2, Phase 3 | Recruiting | 2027-09Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |